Related Experiment Video
Updated: Aug 6, 2026
07:41
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Outcomes Stratified by Adapted Inclusion Criteria After Transcatheter Tricuspid Edge-to-Edge Repair
Giulio Russo1, Daniela Pedicino2,3, Marianna Adamo4
1Department of Biomedicine and Prevention, Cardiology Unit, Policlinico Tor Vergata, University of Rome, Italy.
Summary
Tricuspid transcatheter edge-to-edge repair (T-TEER) trial criteria apply to about half of real-world patients. Those meeting trial criteria for T-TEER show reduced mortality and rehospitalization rates.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Device Trials
Background:
- Tricuspid transcatheter edge-to-edge repair (T-TEER) improves symptoms and quality of life.
- The prognostic impact of T-TEER and trial applicability remain unclear.
- Real-world applicability of T-TEER trial criteria needs investigation.
Purpose of the Study:
- Assess the applicability of TRILUMINATE and Tri.Fr trial criteria to real-world patients.
- Evaluate the impact of trial eligibility on T-TEER patient outcomes.
- Analyze outcomes based on TRILUMINATE and Tri.Fr eligibility separately.
Main Methods:
- Utilized data from the TRIVALVE registry for patients undergoing T-TEER.
- Classified patients into eligible and ineligible groups based on TRILUMINATE and Tri.Fr criteria.
- Conducted separate analyses for TRILUMINATE and Tri.Fr eligibility.
Main Results:
- ~46-50% of 664 real-world patients met TRILUMINATE or Tri.Fr criteria.
- Significant differences in baseline characteristics existed between eligible and ineligible groups.
- Eligible patients demonstrated significantly lower mortality/rehospitalization rates (12-15%) versus ineligible (22-25%).
Conclusions:
- TRILUMINATE and Tri.Fr inclusion/exclusion criteria are applicable to approximately half of T-TEER patients.
- Real-world patients meeting trial criteria exhibit better prognostic outcomes.
- Trial criteria may help identify patients likely to benefit most from T-TEER.
